Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial PHILADELPHIA, Pa. and OXFORDSHIRE, UK.

Adaptimmune Provides Full Contents of

its SITC Abstract for the Phase 1 SURPASS Trial

PHILADELPHIA, Pa. and OXFORDSHIRE, UK., October 15, 2020

- Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware

of the early release of the abstract entitled "Initial safety, efficacy, and product

attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating

an affinity optimized TCR targeting MAGE-A4 and a CD8 co-receptor"

by the Society for the Immunotherapy of Cancer ("SITC") Conference.

The full abstract is attached to this release.

The Company will update on the full dose escalation cohort of

the SURPASS trial (6 patients in total) at the virtual SITC conference on November 11, 2020 at 9 AM EST when posters are made

Adaptimmune is a clinical-stage biopharmaceutical company focused

on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific

Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple

Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020, and our other SEC filings. The forward-looking statements

contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update

such forward-looking statements to reflect subsequent events or circumstances.

S bastien Desprez - VP, Communications and Investor

Juli P. Miller, Ph.D. - Senior Director, Investor

Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8,

a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and

David S. Hong1, Jeffrey

Clarke2, Tanner Johanns3, Partow Kebriaei1, John V. Heymach1, Ahmed Galal2,

Samuel D. Saibil4, Adrian Sacher4, Francine E. Brophy5, Gareth Betts6, Natalie Bath6,

Will Spinner6, Alex Tipping6, Jessica Tucci5, Raymond Luke5, Trupti Trivedi5,

Quan Lin5, Jean-Marc Navenot5, Paula M. Fracasso5, Karen Miller6,

Elliot Norry5, Mark Dudley5, Marcus O. Butler4

Affiliations (Institution, City, State, Country):

1The University of Texas MD Anderson Cancer Center,

Houston, TX, United States of America, 2Duke Cancer Center, Durham, NC, United States of America, 3Washington

University School of Medicine, St. Louis, MO, United States of America,4Princess Margaret Cancer Centre, Toronto, Ontario,

Canada, 5Adaptimmune, Philadelphia, PA, United States of America, 6Adaptimmune, Abingdon, United Kingdom

ongoing SURPASS trial (NCT04044859) evaluates safety and efficacy of next-generation

ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8 co-receptor with the engineered MAGE-A4c1032 T-cell receptor

First-in-human trial in HLA-A*02 positive patients (pts) with advanced

cancers expressing MAGE-A4 antigen by immunohistochemistry. Eligible

pts undergo apheresis, T-cells are isolated, transduced with a Lentiviral vector containing the MAGE-A4c1032 TCR and

CD8 co-receptor, and expanded. Expansion, transduction level, cellular composition and function of the manufactured product

(MP) are assessed in vitro. Prior to infusion, pts receive lymphodepletion with fludarabine 30 mg/m2/day

for 4 days and cyclophosphamide 600 mg/m2/day for 3 days.

As of 16 July 2020, 5 pts (1

with MRCLS, 2 with esophagogastric junction [EGJ] cancers, 1 with ovarian cancer, and 1 with head and neck cancer) were treated

with ADP-A2M4 CD8 (range ~1 to 5.7 billion transduced cells). No DLTs or SAEs have been reported. To date, 1 pt with EGJ cancer

had a partial response (PR per RECIST) and has had progression-free survival >6 months. One pt with head and neck cancer also

had a PR. All other pts have had best overall response of stable disease.

MP expanded by an average of 15.3-fold during manufacturing

(range 5.9 to 25.6-fold). On average, 43% of T-cells in the MP expressed the TCR (range 23 to 63%). The fraction of CD4+ cells

in the final MP varied (range 45 to 84%). Co-expression of the MAGE-A4

TCR and CD8 in CD4+ T-cells in the patient MP enabled CD4+ T-cells to kill tumor target cells directly

in vitro. MAGE-A4 expression in tumor biopsies varied (H-score range 55 to 300). Transduced T-cells were detected

in peripheral blood of all pts. IFN-gamma increased transiently in the serum of 1 pt who responded.

ADP-A2M4CD8 SPEAR T-cells have shown an acceptable safety profile and pts with EGJ cancer and head and neck cancer have

demonstrated evidence of antitumor activity. Translational data and early clinical results indicate that co-expression of the CD8

co-receptor on CD4+ SPEAR T-cells may increase the potency of the product by conferring additional killing activity

to the helper T-cell subset. This dose escalation trial is ongoing and updated clinical and translational data will be presented.